• VistaGen currently developing three novel drug candidates designed to treat central nervous system disorders
• Anxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatment
• Prevalence of depressive disorders in U.S. workplace is estimated to result in economic impact of over $210.5 billion per annum
• COVID-19 pandemic has further exacerbated these conditions, with number of patients displaying anxiety symptoms rising by 93% YoY between January – September 2020

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications which go beyond the standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders. Anxiety disorders have been found to be the most common mental illness in the U.S., affecting 40 million adults in the United States age 18 and older, or 18.1% of the population. However, while most anxiety disorders are highly treatable, only 36.9% of those suffering receive treatment (https://ibn.fm/z00SV). Two of the most common mental health conditions, namely depression and anxiety, are estimated to cost the global economy $1 trillion each year—and these conditions have been further exacerbated during the COVID-19 pandemic (https://ibn.fm/tmPyO). A recent study carried out by Mental Health America found that the number of people looking for help with anxiety and depression has skyrocketed in 2020; between January to September 2020, the number of people screening for anxiety symptoms rose by 93% relative to 2019 while those found to have symptoms of depression rose by 62% year-on-year (https://ibn.fm/rDGWQ). Within the U.S. workforce, the prevalence of major depressive disorders (MDD) has been estimated at 7.6%, with the total economic burden now estimated to be over $210.5 billion per year. Nearly half of these costs are attributed to the work place, including absenteeism (missed days from work) as well as reduced productivity while at work, whereas 45-47% are due to direct medical costs, which are shared by employers, employees, and society (https://ibn.fm/ev3Ns). The impact of CNS-related disorders on patient lives and the wider global economy, coupled with the potential risks associated to conventional benzodiazepine drugs – the class of medicines approved to treat conditions such as anxiety, insomnia and seizures—have increased the urgent need for pharmaceutical companies to develop safer alternatives to the traditional medication available to patients today. VistaGen Therapeutics has sought to address this situation through its product portfolio, consisting of three novel drug candidates – namely, PH94B, PH10 and AV-101, which seek to target a wide variety of central nervous system (“CNS”) disorders through medications designed to present fewer side-effects relative to their commonly used peers. PH94B is a fast-acting, non-systemic and non-sedating neuroactive nasal spray which is being developed as an acute treatment of anxiety in adults afflicted with social anxiety disorder (“SAD”). It has been designed to displace benzodiazepines – which have recently been required by the U.S. Food and Drug Administration to describe the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions consistent to all medicines in this class (https://ibn.fm/wgF1B). PH10 is an investigational synthetic neuroactive nasal spray in development as a potential rapid-onset therapeutic alternative in a wide range of depression-related disorders. Mental health conditions have been found to have a substantial effect on all areas of life, including socially and economically. Through the development of its three novel drug candidates, VistaGen Therapeutics has sought to address the growing need for safe and effective treatments to a disease whose spread had gone widely unchecked in recent years. NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

• Recent study reports that consumers are opting for single-serve beverages; bottled water outperforms carbonated beverages
• WTER’s flagship product — Alkaline88 — now available in easy-to-carry, two-liter single-serve bottles
• Company’s A88 flavor-infused water offering gaining significant market share, available in growing number of spaces

A growing number of consumers who drink and snack throughout the day are turning to single-serve, ready-to-drink beverages, often found most easily at c-stores, according to a recent Shop Association report (https://ibn.fm/Q5Hw7). Recognizing the market opportunity, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) recently launched a new 2-liter single-serve option to meet that increased customer demand (https://ibn.fm/aysjl). “Overall, the beverage industry is positioned to remain strong throughout the coming years with bottled water outperforming carbonated beverages,” reported the Shop Association study, which also noted that convenience is a key driver in the segment growth. “A recent global Packaging market research study from the Association for Packaging and Processing technologies found that customers tend to pick up grab-and-go foods for purchase as an impulse. Retailers and brands can capitalize on this impulse spending while finding ways to implement environmentally friendly messages and customizable elements into foodservice packaging. Grab-and-go programs for a product in a growing category is one way to increase incremental sales for both brands and retailers.” Committed to meet the needs of consumers and retailers alike, WTER unveiled its flagship product — Alkaline88(R) — in new, easy-to-carry, two-liter bottles, available for purchase alone or in a six pack. “This unique six pack complements our existing line-up, especially our single-serve offerings, which continue to do well in the current environment,” said The Alkaline Water Company’s president and CEO Ricky Wright. “The two-liter format is extremely popular in the carbonated soft drinks segment but virtually nonexistent in the bottled water category.” With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and perfectly represents the company’s trademarked Clean Beverage label. In addition to Alkaline88 and in another show of its astute awareness of consumer demand and interest, The Alkaline Water Company also offers A88 Infused(TM). Available in seven all-natural flavors (with new flavors on the horizon), the flavor-infused water offering is gaining significant market share and is available in a growing number of spaces (https://ibn.fm/ndOgp). “Demand for our single-serve offerings are at an all-time high, and we are rapidly growing shelf space for our A88 Infused flavored waters,” stated Wright. “Our channel partners are some of the leading players in the all-natural vertical and give us a reach into nearly 40,000 retailers nationwide. Our sales team is working closely with our partners to create ‘speed to market’ programs, including promotion and incentives to drive further momentum. We are doing a great job creating new leads, and currently, our flavors are carried by or have placement commitments from nearly 13,200 stores across the U.S. . . .Our A88 Infused brand is now available in some of the top supermarkets, retailers, and wholesalers, and we expect this trend to accelerate throughout our fiscal year.” Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. In addition to its A88 Infused(TM) water line, the company also recently launched A88CBD, a line of CBD-infused beverages.  For its topical and ingestible offerings, A88 Infused products include both the company’s lab-tested, hemp extract salves, balms, lotions, essential oils, and bath salts, along with hemp extract powder packs, oil tinctures, capsules, and gummies. For more information, visit the company’s websites at www.A88CBD.com and www.TheAlkalineWaterCo.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• BRSF is modernizing brain diagnostics with cost-effective, disposable solutions that help minimize risk of spreading disease
• AI-assisted analysis allows for processing of relevant data in real time at high speed for early diagnosis, higher rate of successful treatments

Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics by employing cutting-edge tech to bridge the widening gap in access to quality care. BRSF is achieving this through cost-effective and disposable substitutes to existing solutions that improve patients’ access to neurological care. Currently, BRSF is in phase two of a three-phase plan for development. Phase one of development occurred in 2018–2019 with the inception of portable, clinical-grade, easy-to-use neurological devices. The company’s two FDA-cleared products — NeuroCap(TM) and NeuroEEG(TM) — are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific. Additional devices currently under development address routine EEG, pediatric EEG, long-term monitoring, AI and telemedicine. The disposable and cost-effective NeuroCap could end up being a viable tool in the treatment of those infected with COVID-19. Over 80% of hospitalized patients from the pandemic have been displaying neurological symptoms (https://ibn.fm/nmbSd). The disposable aspect of the NeuroCap is key in the treatment as reusable EEG electrodes have the potential for putting patients in further risk (https://ibn.fm/K4pg4). Phase two of development, which is currently ongoing, is the creation of a cloud-based, secure infrastructure to transmit patient data between patients and teleneurologists.  The demand for neurological services is growing. According to the American Academy of Neurology, the demand for neurologists is outpacing the supply. It is estimated that by 2023, the United States will be short anywhere from 20,600 to 39,100 specialists, including neurologists (https://ibn.fm/HpdcT), which means patients will likely end up waiting to see a neurologist. Creating a cloud-based infrastructure could allow patients to access this vital care. Phase three (planned for 2021–2022) focuses on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists. Brain Scientific is developing several new products for the AI market, incuding the following:

• Brain E-Tatoo is a subcutaneous, minimally invasive, implantable EEG electrode designed for long-term monitoring to detect epileptic seizures.
• Brain AI is not one product but rather a database of biomarkers that work to develop algorithms to detect abnormal activity.

AI-assisted analysis is vital in moving forward for better care and treatment for patients. A massive amount of data and published studies has been created as the healthcare community discovers new medicines, new applications of medication, new precautions and new approaches to patient care. More data has been produced than a human can process. AI-assisted analysis allows for the processing of relevant data in real time at high speed to allow for the early diagnosis and probabilistic success rates for various treatments. This approach, one in which Brain Scientific is leading the way, provides a tool for the neurologist to provide optimal care to each and every patient. For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• China’s government has set out its next 5-year plan, highlighting promotion of electric vehicles as key tenet underpinning their environmental policies
• Net Element’s reverse merger with EV manufacturer Mullen Technologies is expected to close by 4Q2020, with Net Element expected to divest its legacy payments business following the deal
• Company aims to begin selling K50 Dragonfly sportscar by 2Q2021, recently began pre-sales for its wholly self-developed EV SUV, the Mullen MX-05
• US has followed in China’s footsteps, with Presidential candidate Joe Biden encouraging mass EV adoption as key policy initiative

Net Element (NASDAQ: NETE), a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through its binding letter of intent to merge with privately-held Mullen Technologies Inc., may have timed its move to perfection. The fifth plenum of the Chinese government concluded on October 29 following a four-day meeting. This year, the semi-annual gathering of China’s top leaders had a special task – finalizing the blueprint for the 14th Five-Year Plan, which will set out China’s economic policies for the period from 2021 – 2025 (https://ibn.fm/koCs5). One of the key undertakings adopted by the Chinese government during the plenum involved delineating a series of measures set to govern the development of the nation’s budding new energy vehicle (“NEV”) sector between 2021-2035, which aim to accelerate the country’s development into an automotive powerhouse. The plan released by the State Council, China’s cabinet, listed a number of broad guidelines, namely – to improve the domestic Chinese auto sector’s capacity for technological innovation, build advanced industry ecosystems, and encourage further industrial integration and development. More specifically, the plan stated the Government’s ambitions of bringing the average power consumption of new, purely electric passenger cars down to 12 kWh/100 km while raising the market share of new NEVs within total automotive sales to 20% by 2025. By 2035, the Government aims to encourage the mass adoption of purely electric automobiles as a replacement to conventional internal combustion engine powered cars, while ensuring that all vehicles used in public transportation are completely electrified (https://ibn.fm/4QsI9). Net Element and Mullen Technologies have revealed plans to begin their foray into the US electric vehicle market through their partnership with Chinese EV manufacturer, Qiantu Motors, with the aim of marketing and selling the latter company’s vehicles in the US. The joint-venture’s first product will be the K50 Dragonfly – an all-electric, two-seat, carbon-fiber-bodied sports car which can go from 0-100 km/hr in 4.6 seconds (faster than a Porsche Boxster) and which is set to begin deliveries from 2Q2021 onwards. The company plans to follow on from their introductory model with the manufacture and sale of an entirely self-produced EV SUV, the Mullen MX-05, by the second quarter of 2022—with hopes of reaching a production threshold of 35,000 vehicles per annum by 2026. Mullen recently announced that the company has begun taking pre-orders for the MX-05 as of October 1, 2020 through its website as well as through any Mullen retail location in the U.S. China’s NEV policies, while considerably more ambitious than those professed by the rest of the world, have resonated elsewhere around the globe. During his campaign, Democratic Presidential candidate Joe Biden set out four key targets driving his goals to encourage EV adoption – building 500,000 public EV charging stations by 2030, restoring the full EV tax credit, shifting government fleets to electric cars, and developing a new fuel economy target (https://ibn.fm/zqFBK). Economies and governments the world over have positioned themselves for the mass promotion and adoption of electric vehicles as a key pillar underpinning their environmental goals. Through their upcoming tie-up (pending shareholder approval), as well as through their recent operational initiatives, Net Element and Mullen Technologies find themselves well positioned to respond to the rising tide of demand within the electric vehicle sector. For more information, visit the company’s website at www.NetElement.com. NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• Josemaria Resource’s flagship copper-gold-silver Josemaria Project is located in Argentina’s San Juan province
• Company has recently published its NI 43-101 compliant feasibility study on the project
• Mine expected to generate an average annual production of 136,000 tonnes of copper, 231,000 ounces of gold and 1,164,000 ounces of silver over its 19-year life
• Study indicates $1.53 billion after-tax Net Present Value at an 8% discount rate, 15.4% Internal Rate of Return at metal prices of $3.00 per pound copper, $1,500 per ounce gold, $18 per ounce silver
• The Josemaria Project return increases to $US2.3Bn After-Tax NPV₈ and 18.5% IRR as calculated by metal prices on November 12, 2020 of $US3.14/lb Cu, $US1883/oz Au and $US24.33/oz Ag (https://ibn.fm/zR4Ip)
• JOSE anticipates a 3.8-year, rapid payback period on initial capital investment from start of production

Josemaria Resources (TSX: JOSE) (OTC: JOSMF) (Nasdaq Stockholm: JOSE), a Vancouver, BC, Canada-based natural resources company, recently released the results of an independent NI 43-101 compliant feasibility study on its flagship project, the wholly-owned copper-gold-silver Josemaria Project located in the San Juan Province, Argentina (https://ibn.fm/DlDYg). Prepared by a team led by Fluor Canada Ltd. alongside SRK Consulting (Canada) Inc. and Knight Piesold Ltd., the study revealed a robust and relatively low-risk project with a rapid 3.8-year payback period.  The mine is planned as an open pit operation feeding a conventional process plant at a Life-of-Mine average rate of 152,000 tonnes a day over a 19-year mine life.

The feasibility study projects average annual metal production of 136,000 tonnes of copper – equivalent to nearly 0.7% of annual global copper production, 231,000 ounces of gold and 1,164,000 ounces of silver on average over its life span with higher output early in the mine life. Similarly, the study indicated a $1.53 billion after-tax Net Present Value at an 8% discount rate and a 15.4% Internal Rate of Return at metal prices of $3.00 per pound copper, $1,500 per ounce gold, and $18 per ounce silver. At spot prices on November 12, 2020 ($US3.14/lb Cu, $US1883/oz Au, $US24.33/oz Ag) these numbers increase to $US2.3Bn After-Tax NPV₈ and 18.5% IRR.

“We are extremely pleased with the results of the Feasibility Study at Josemaria which indicates that this is one of the very few readily developable copper-gold projects in the world today,” said Josemaria Resources President and CEO Adam Lundin. “I believe the study results will allow us to unlock various financing opportunities as we move toward construction.”

The company estimates that the project’s anticipated capital costs, which include engineering, procurement, construction, management, on- and off-site infrastructure and contingency, amount to approximately $3.09 billion, with a further $940 million in sustaining capital  required to maintain operations at full production over the entire 19-year life span of the mine (https://ibn.fm/8svkR).

The feasibility study includes an optimised mine production plan with average grades in the initial three full years of production notably better than the life of mine averages, supporting strong investment payback potential and driving a 3.8-year payback period from start of production.

Following the release of the feasibility study, the Josemaria Project is expected to continue progressing rapidly towards construction. Basic engineering work is currently forecast to begin in the first quarter of 2021, followed by detailed engineering in the third quarter of 2021. The construction of a pioneering access road is planned to commence in the third quarter of 2021 predicated on appropriate permitting and financing milestones being met. Once all necessary conditions have been met, Josemaria Resources anticipates commencing the bulk earthworks on site during the fourth quarter of 2022. Commercial production is ultimately forecast to commence by 2026.

Once operational, the Josemaria Project is estimated to derive 71% of its revenues through the production of copper, with a further 27.5% contributed by gold and 1.5% from silver. Global demand for copper has shown a steady growth trajectory over the years- with the global copper market expected to achieve an annual value of $222.1 billion by the end of 2026.  Gold, a traditional store of value and safe haven investment has seen its price appreciate significantly over the course of the year touching a high of $2,067.15 an ounce in early August 2020 (www.gold.org)

For more information, visit the company’s website at www.JosemariaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to JOSMF are available in the company’s newsroom at https://ibn.fm/JOSMF

• Sustainable Green Team Ltd reported its financial results for 3 months ending Sept. 30, 2020
• Company reported 3Q20 revenues of $5.9 million, gross profit of $422 thousand, taking 9M20 revenues to $24.5 million and gross profit to $5.5 million
• SGTM also provided status update regarding its retailing tie-up with Circle K convenience stores, the geographical scope of which has now increased to include fourth region

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has recently published its financial results for the third quarter of 2020. The company has seen its fiscal revenues rise to total $24.5 million over the first nine months of 2020. For the fiscal quarter ending September 30, 2020, SGTM reported $5,907,155 in revenue, $422,133 in gross profit and $36,140,923 in total assets, with a strong position of $5,936,798 in cash and liquid investments. In aggregate, that took the company’s total revenues for the first nine months of the year to $24,544,820 while recording $5,503,905 in gross profit (https://ibn.fm/aBJQN). The company also seized the opportunity to expand on its numerous achievements over the course of past three months:

• Completion of company name and trading symbol change as of July 21, 2020
• SGTM awarded IPEMA certification to recycle tree and storm waste into public playground surfacing material on July 23, 2020, providing the company with access to a $4 billion market
• Completion of the dual line mulch bagger and fully automated electric grinding screening operation at Waste Management’s Apopka, Florida-based facility, increasing its mulch manufacturing capability by 4 million bags per year
• Addition of new grapple hauling trucks to the Company’s fleet, with each truck capable of hauling 1,250 loads per annum, equivalent to $400 thousand in gross revenue
• Obtaining a permit to accept debris and manufacture mulch at the company’s state-of-the-art, 100,000 square foot Jacksonville facility

“I am proud of our team and the progress we have made this year in achieving these key milestones,” commented Sustainable Green Team’s CEO and Director Tony Raynor in reference to the results. “We plan to proceed in a similar manner during the remaining quarter and end 2020 on a strong note. In keeping with that aim, we have already completed our two-year audit to commence our Form 10 process, which will enable us to begin 2021 as a fully reporting company and uplist accordingly.” Separately, the company also took the opportunity to announce that it had signed a new mulch contract for 2021 with Circle K convenience stores, a subsidiary of Alimentation Couche-Tard, Inc (OTC: ANCUF). The original agreement with Circle K, signed in October 2020, was modified to add an additional region to the initial three regions in which SGTM’s mulch products would be marketed, thereby increasing the potential revenue potential from the tie-up (https://ibn.fm/ya2nW). To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/vtjJ2. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Under the vendor agreement with the world’s leading short-term rental property management company, InsuraGuest Technologies will provide coverage to tens of thousands of Guesty clients
• The current size of the vacation rental market is valued at approximately $87.61 billion and is expected to grow to an estimated $113.9 billion by 2027
• InsuraGuest is not only handling digital insurance in the hospitality sector but also branching out to offer coverage options in multiple other industries

Leading insurtech company InsuraGuest Technologies (TSX.V: ISGI) has announced that it has entered into a signed vendor agreement with Guesty, the world’s foremost short-term rental property management company. Guesty provides an end-to-end solution platform for property managers and management companies to simplify and automate operational needs for short-term rentals (https://ibn.fm/Aklcz). Under the vendor agreement, InsuraGuest will integrate with Guesty property management software through the company’s proprietary API. “Upon completion of our API integration, InsuraGuest will be available to Guesty’s tens of thousands of clients with a product that not only protects their properties but also responds to claims made by their guests,” said Douglas Anderson, CEO and Chairman of InsuraGuest Technologies. The integration will allow Guesty’s users to transfer certain liabilities to InsuraGuest’s Hospitality Liability Policy. As a result, these short-term rental properties can lower claim ratios and their risk profile, which may lead to a decrease in general liability or homeowner’s insurance premiums. InsuraGuest Hospitality Liability coverages are the first line of defense for member hotels and vacation rental properties. The policy provides an additional layer of protection that prevents the need for general liability claims if an InsuraGuest covered claim occurs. InsuraGuest responds to the claims of guests on a primary basis, covering accidental in-room property damage, theft, accidental death and dismemberment, and accidental medical expenses. The coverage fills the gap that is left by other policies, inserting protection that responds to the property when guests experience mishaps. InsuraGuest will provide Guesty’s clients with an additional layer of protection while providing them with competitive pricing, reduced risk, the potential for lower liability insurance costs, quick claim compensation turnaround, and improved guest experiences, giving them a worry-free stay. The short-term rental entity extends coverage to every guest, activating the coverage upon check-in. The charge for the coverage is placed in the guest’s folio or is bundled into the nightly rate. Regarding the vendor agreement between InsuraGuest and Guesty, Alon Eitan, Guesty’s director of strategy and business development, said, “We are excited to begin our relationship with InsuraGuest. Providing our customers with access to vendors like InsuraGuest helps protect their properties and provide peace of mind.” Guesty works with several major online travel agencies, providing end-to-end solutions for companies like Airbnb, Vrbo, and TripAdvisor. Their clients also use Guesty’s guest-centric tools, including Unified Inbox, 24/7 Guest Communication Services, Automation Tools, Payment Processing, and now InsuraGuest’s Hospitality Liability Policy, as well. The agreement helps InsuraGuest strengthen its position as an insurance solution provider in the vacation rental market, a sector that is constantly expanding. The current size of the vacation rental market is valued at approximately $87.61 billion, and it is expected to grow at a CAGR of 3.4% to an estimated $113.9 billion by 2027 (https://ibn.fm/KxjbY). InsuraGuest Technologies is transforming how we view insurance, providing digital insurance reimagined, reinvented, and revolutionized. InsuraGuest aims to transform the way insurance is delivered with the revolutionary idea that insurance should be bought, not sold. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• EV battery prices becoming increasingly economical, dropping 87% in less than decade with additional 30% drop predicted by 2023
• NETE plans to divest payments processing model to enter EV industry through merger with privately-held Mullen Technologies Inc.
• Battery-focused subsidiary Mullen Energy part of US expansion, thousands of jobs expected to be created
• Pre-orders for MX-05 SUV commenced, production expected to start in 2021

The average real price of electric vehicle (“EV”) batteries has dropped 87% in less than a decade (https://ibn.fm/GRCa9) and is projected to drop even further due to technological innovations destined to make EVs a viable alternative to gas-powered vehicles. Net Element (NASDAQ: NETE), through its pending merger with Mullen Technologies, will be well-positioned to benefit from this trend through Mullen Energy, a Mullen subsidiary focused exclusively on advancing battery technology.

While the current decrease in battery prices is impressive, analysts predict an even further 30% drop over the next three years, reaching a point where EVs will start to reach price parity with internal combustion engine vehicles. A combination of factors concerning battery technology is suggested to contribute to this shift that include cell design, production innovation, changes in the anode materials, changes in the cathode materials, and innovations that will change how the battery is integrated into the car.

Mullen Technologies is already well on its way to making substantial progress on battery technology through subsidiary Mullen Energy. Along with Mullen Auto Sales, Mullen Finance Corp. and a digital marketplace called CarHub, Mullen is well-positioned to expand its footprint in the United States with plans to expand and construct new production facilities that will bring thousands of jobs to the country.

Pre-orders for the five-passenger MX-05 SUV have already started, and manufacturing is expected to commence in the third quarter of 2021 with delivery dates set for the second quarter of 2022. Along with the MX-05, Mullen is planning to build and lease 1.3 million square feet of assembly and manufacturing space in Washington to produce the Dragonfly K50 electric sports car.

The time has never been better to expand into the EV industry. Research by BloombergNEF has suggested that nearly half of all passenger car sales in China will be electric by 2025 (https://ibn.fm/6ZwNQ). Along with the falling prices of batteries, EV mandates across the world paired with changes in fuel regulations are destined to contribute to EV dominance, projected to take over the municipal bus market by 81%, light commercial vehicle sales at 56%, and the medium commercial market at 31%.

A global financial technology and value-added solutions group, NETE has traditionally supported electronic payments acceptance in an omni-channel environment that included point-of-sale, e-commerce and mobile devices. Once ranked as one of the fastest-growing companies in North America by Deloitte, NETE plans to divest its payments-as-a-service business model to enter the electric vehicle industry through a reverse-merger with California-based Mullen Technologies.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at  http://ibn.fm/NETE

• Pure Extracts Technologies trading on CSE under symbol PULL
• Company runs first oil extraction, distillation under new licenses
• PULL products highly desired by provincial dispensaries as consumers gravitate to FSO

An emerging leader in extraction, Pure Extracts Technologies (CSE: PULL) began trading on the Canadian Securities Exchange (“CSE”) earlier this month under the symbol ‘PULL’. The plant-based extraction Company focuses on cannabis, hemp, and functional mushroom sectors and uses its proprietary CO2 extraction methodology to obtain full-spectrum oil (“FSO”) from cannabis and hemp biomass. “We are pleased to have listed on the Canadian Securities Exchange as a significant first step towards Pure Extracts’ continual expansion within the emerging extraction space,” said Pure Extracts’ CEO Ben Nikolaevsky. “There currently is a tremendous opportunity for growth in consumer natural health products, for which we plan on playing a pivotal role within the supply chain mechanism by providing full spectrum oil products for the cannabis, hemp and functional mushroom space.” In a letter to shareholders, Nikolaevsky called the CSE listing a “major milestone” that gives the Company’s shareholders liquidity in the public markets and the Company access to capital. In that same letter, he noted that Pure Extracts recently received its Standard Processing license from Health Canada. “We have spent the last 6 weeks commissioning our equipment for commercial production,” he said. “On Nov. 4^th, we ran our first oil extraction and distillation under our licences. We are super excited about our first trial run.” Nikolaevsky noted that Pure Extracts was running required samples over the coming weeks to “apply for our Sales license with Health Canada, which will allow us to bring our vape brand, Pure Pulls and our edibles brand, Pure Chews to the consumer market. Our products are highly desired by the provincial dispensaries as consumers are gravitating to full-spectrum oil (‘FSO’), which we specialize in.” “Pure Extracts anticipates starting its extraction tolling business in December with its first batch being scheduled for extraction early in the month”, said Nikolaevsky. In addition, now that the Company can provide samples, it is bidding on several contracts in the white label arena. “Although the Health Canada approval took longer than we planned for, we believe we can capture some meaningful volumes in the white label area into Q1 2021,” he said. In addition, Pure Extracts is entering the functional mushroom space “We intend to launch these products in Q1 from an online portal that we are developing. Functional mushrooms have been identified as the new ‘wonder’ product in the wellness space and have been rapidly growing in popularity, so this is a very exciting move for us,” he noted. Pure Extracts Technologies Inc., headquartered in Pemberton, British Columbia, is a plant-based extraction Company with a new vertical in functional mushrooms. The Company is positioned to be a successful extraction Company and a leader in the rapid development and commercialization of functional mushroom products. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease
• The company plans a complex, multi-armed Phase 2 trial of its candidate Berubicin in hopes that the drug candidate may ultimately gain an expedited pathway to approval and registration from the FDA
• The trial for combatting Glioblastoma Multiforme is expected to begin next year, and on Nov. 12 the company’s officers launched a webinar to provide information on how the trial will be designed
• CNS Pharmaceuticals is also preparing, in partnership with its sub-licensee WPD Pharmaceuticals, for two additional trials of Berubicin to be conducted in Poland including the first-ever Phase 1 pediatric trial as well as a parallel Phase 2 trial in adults

A biopharmaceutical company working to find a better way of treating an aggressive form of brain tumor, Glioblastoma Multiforme (“GBM”), which is currently regarded as incurable and ultimately fatal, announced recently that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review. It includes a novel clinical trial design it hopes will lead to a breakthrough, and on Nov. 12 company officers discussed the design for the upcoming Phase 2 U.S. trial in a webinar open to the public (https://ibn.fm/bV2e2). “I would like to remind everyone that this upcoming Phase 2 trial will build on the success of the Phase 1 trial of Berubicin in which the clinical benefit response was 44 percent, including one patient … who had a durable complete response and is still alive and cancer-free today, 14 years after treatment with Berubicin, and another two patients with partial responses, who had reductions of greater than 25 percent in the size of their tumors,” CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco told the webinar audience. CNS Pharmaceuticals’ lead drug candidate in treating GBM, Berubicin, is an anthracycline. “Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers, including breast, ovarian, lung, lymphoma and leukemia, and other malignancies as well. However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain,” Climaco said. “Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies,” he said. CMO Dr. Sandra Silberman explained that the Phase 2 trial will allow a real-time comparison between Berubicin patients and patients receiving the normal standard of care, using “interim analyses that could impact and in fact reduce the numbers of patients required to establish the effectiveness of Berubicin.” Under the parameters of the trial, 243 patients will participate, 162 of them receiving Berubicin and the other 81 receiving the chemotherapy drug lomustine. About 60 study centers will be used in North America, Europe and the Asia-Pacific region. Once 50 percent of the patients have been in the study for six months, the interim analysis will begin. “We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” Silberman said. The study will also be designed to preserve patient safety even with the continuation of the COVID-19 pandemic and GBM patients who don’t ultimately qualify for the study will be allowed other avenues to try Berubicin under U.S. “right to try” laws. “We now have a drug supply manufactured and will do our best to get these patients that could benefit from Berubicin and have failed standard therapies (to where they) can be part of these parallel studies for which we will continue to accrue safety and efficacy information,” Silberman said. Additional information about such opportunities will be posted on the company’s website. Climaco said the complex trial design is not only the most potentially beneficial for studying Berubicin’s effects, but ultimately the most cost-effective design for the company’s shareholders as well because the Phase I trial not only showed the drug’s potential for safe use, but efficacy also. “Rather than conduct a single-arm trial of Berubicin that would likely simply show us more interesting positive data, we chose to effectively allow our Phase 2 trial to incorporate an arm receiving standard of care such that any significant impact of Berubicin could be better analyzed,” he said. Because the trial is expected to eventually cost $30 million to $35 million, Climaco said the company is taking a phased fund-raising approach over the next two to two and a half years, progressing from one success to the next rather than trying to raise all of the capital at once. Sound results from the Phase 2 trial could potentially sway the FDA to grant Berubicin an expedited pathway to approval, which would save time in the long run. “Which is of course the valuable important commodity here,” he said. CNS Pharmaceuticals is also preparing, in partnership with its sub-licensee WPD Pharmaceuticals, for two additional trials of Berubicin to be conducted in Poland. The first is a first-ever Phase 1 pediatric trial. The secondi s a parallel Phase 2 trial in adults that will be used as additional data to supplement and strengthen the data submitted to the FDA from the primary trial conducted by CNS Pharmaceuticals. CNS Pharmaceuticals is also developing a drug candidate known as WP1244 with a DNA-binding agent that preclinical studies have shown to be 500 times more potent than chemotherapy drug daunorubicin in stopping tumor cell expansion. This drug is undergoing additional pre-clinical studies in preparation for a potential future Phase 1 clinical trial. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP